T Cell-Specific Sirna Delivery Suppresses HIV-1 Infection in Humanized Mice

Priti Kumar,Hong-Seok Ban,Sang-Soo Kim,Haoquan Wu,Todd Pearson,Dale L. Greiner,Amale Laouar,Jiahong Yao,Viraga Haridas,Katsuyoshi Habiro,Yong-Guang Yang,Ji-Hoon Jeong,Kuen-Yong Lee,Yong-Hee Kim,Sung Wan Kim,Matthias Peipp,Georg H. Fey,N. Manjunath,Leonard D. Shultz,Sang-Kyung Lee,Premlata Shankar

DOI: https://doi.org/10.1016/j.cell.2008.06.034

IF: 64.5

2008-01-01

Cell

Abstract:Evaluation of the therapeutic potential of RNAi for HIV infection has been hampered by the challenges of siRNA delivery and lack of suitable animal models. Using a delivery method for T cells, we show that siRNA treatment can dramatically suppress HIV infection. A CD7-specific single-chain antibody was conjugated to oligo-9-arginine peptide (scFvCD7-9R) for T cell-specific siRNA delivery in NOD/SCIDIL2rgamma-/- mice reconstituted with human lymphocytes (Hu-PBL) or CD34+ hematopoietic stem cells (Hu-HSC). In HIV-infected Hu-PBL mice, treatment with anti-CCR5 (viral coreceptor) and antiviral siRNAs complexed to scFvCD7-9R controlled viral replication and prevented the disease-associated CD4 T cell loss. This treatment also suppressed endogenous virus and restored CD4 T cell counts in mice reconstituted with HIV+ peripheral blood mononuclear cells. Moreover, scFvCD7-9R could deliver antiviral siRNAs to naive T cells in Hu-HSC mice and effectively suppress viremia in infected mice. Thus, siRNA therapy for HIV infection appears to be feasible in a preclinical animal model.